55 results
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
13 Mar 24
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
4:16pm
, for an estimated annualized cost savings of more than $25 million.
Expected SG&A and R&D expenses for 2024 reduced from $301.5 million in 2023 to $250-265 … sales payable through the first half of 2024, and CIMERLI® COGS includes a low to mid 50% royalty on gross profits.
Research and development (R&D) expense
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
6 Nov 23
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
4:31pm
Executive Officer. “Our net revenues of $74.6 million in the third quarter represent an increase of 27% compared to Q2, and our SG&A plus R&D costs year … (R&D) expense for the three months ended September 30, 2023 and 2022 was $25.6 million and $45.8 million, respectively. For the nine months ended
8-K/A
EX-99.2
h42 a0fgxzd90q
6 Nov 23
Report of Independent Registered Public Accounting Firm
6:07am
8-K/A
EX-99.1
uekpd32yf6b7c
6 Nov 23
Report of Independent Registered Public Accounting Firm
6:07am
8-K
EX-99.1
sq6m3
27 Oct 23
Regulation FD Disclosure
4:19pm
8-K
EX-99.1
0z78rsw2e8la
2 Aug 23
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
4:05pm
424B3
wm91509fun yrv4
26 Jul 23
Prospectus supplement
4:59pm
S-4/A
pyhz3
24 Jul 23
Registration of securities issued in business combination transactions (amended)
4:42pm
S-4
0uelgvt1mcbof p10
7 Jul 23
Registration of securities issued in business combination transactions
5:03pm
425
rzutc urz71
16 Jun 23
Business combination disclosure
5:17pm
425
kd949v9 8zuou8y6
16 Jun 23
Business combination disclosure
5:14pm
425
z3ro49wlai
16 Jun 23
Business combination disclosure
5:14pm
425
bm4u6t
16 Jun 23
Business combination disclosure
5:12pm
425
vfark5k5ihiz
16 Jun 23
Business combination disclosure
5:11pm
425
b8t6mzauc2sm1
16 Jun 23
Business combination disclosure
8:08am
425
a3vsrxr2poze9
16 Jun 23
Business combination disclosure
7:09am
8-K
EX-99.1
dvfmdajy7k
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am